Business UpdateNov 5, 2026, 09:16 AM
Ascentage Pharma to Present Multiple Trial Data at ASH 2026
AI Summary
Ascentage Pharma announced multiple clinical and preclinical data presentations at the 68th ASH Annual Meeting. Key highlights include oral presentation of APG-5918 Phase 1 data in R/R TCL showing promising efficacy, and poster presentations detailing combination therapies for various hematologic malignancies including olverembatinib and lisaftoclax. The company also presented preclinical findings on APG-5918 and lisaftoclax in DLBCL models.
Key Highlights
- APG-5918 Phase 1 study in R/R TCL showed 44.7% ORR (65.0% at 600 mg QD) with manageable safety.
- Olverembatinib + blinatumomab achieved 80.0% MMR in R/R Ph+ BCP ALL/CML-LBP.
- Olverembatinib + lisaftoclax showed 90.0% ORR in pediatric R/R Ph+ ALL, with 69.2% MRD negativity.
- Olverembatinib + blinatumomab + chemo achieved 100% CR in newly diagnosed pediatric Ph+ ALL.
- Olverembatinib + lisaftoclax + AZA showed 30% ORR in venetoclax R/R AML.
- Preclinical DLBCL models showed synergistic antitumor activity with APG-5918 + lisaftoclax.
Price Impact
More from AAPG